Hangzhou Biotest Biotech Co.,Ltd. (SHA:688767)

Market Cap	5.89B +65.9%
Revenue (ttm)	478.69M -7.7%
Net Income	102.57M -1.7%
EPS	0.65 -7.8%
Shares Out	146.32M
PE Ratio	61.62
Forward PE	n/a
Dividend	1.07 (2.66%)
Ex-Dividend Date	n/a

Volume	8,200,191
Average Volume	3,205,131
Open	37.50
Previous Close	37.50
Day's Range	37.14 - 41.38
52-Week Range	22.51 - 50.98
Beta	0.57
RSI	56.76
Earnings Date	Apr 25, 2026

About Hangzhou Biotest Biotech

Hangzhou Biotest Biotech Co.,Ltd. engages in the research and development, manufacture, sale, and service of in vitro diagnostic assays and reagents, and instruments in China and internationally. The company offers medical test products for fertility health, cardiology, oncology, inflammation, biochemistry, and various infectious diseases. It also provides veterinary test kits; fluorescence immunoassay rapid test kits; and other rapid testing kits. In addition, the company is widely utilized across various medical institutions, judicial testing...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 622
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688767

Financial Performance

In 2024, Hangzhou Biotest Biotech's revenue was 559.40 million, an increase of 26.53% compared to the previous year's 442.11 million. Earnings were 169.52 million, an increase of 59.01%.